Clinical Trials Browser

Phase 1/2 × Carcinoma, Renal Cell × Ramucirumab × Clear all

NCT02082210 2020-12-19

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

Phase 1/2 Completed

97 enrolled 20 charts

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Liver Neoplasms